Status:
TERMINATED
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Asthma
COPD
Eligibility:
All Genders
12+ years
Brief Summary
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
Detailed Description
In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch patients to the inhaler wit...
Eligibility Criteria
Inclusion
- Written informed consent has been obtained.
- Male or female patients with a diagnosis of asthma and/or COPD whose budesonide-formoterol DPI was switched to another budesonide-formoterol DPI at pharmacy between 1st July 2018 and 1st March 2019 (referred to as the eligible switch).
- Age ≥12 years at time of switch.
- Treated with budesonide-formoterol for at least 12 months before the eligible switch (pre-switch period) and 12 months after the eligible switch (post-switch period). Re-switch(es) of inhaler are allowed during the post-switch period.
Exclusion
- 1\. Patient has declined participation in the study or failed to respond to the invitation to participate.
Key Trial Info
Start Date :
December 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 14 2021
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04663386
Start Date
December 10 2020
End Date
September 14 2021
Last Update
September 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Flattum Legesenter
Hønefoss, Norway